Gleevec was described in Video 2 5 as a drug targeting the

Last updated: 8/19/2023

Gleevec was described in Video 2 5 as a drug targeting the BCR ABL fusion protein an abnormal kinase encoded by an oncogene on the Philadelphia chromosome that is frequently found in chronic myelogenous leukemias Gleevec is a kinase inhibitor that suppresses BCR ABL fusion protein activity and reduces tumor growth rate effectively in many CML patients with a Philadelphia chromosome However as with all mutation targeting chemotherapeutic drugs the efficacy of Gleevec declines over time in any given patient and eventually it stops working to suppress tumor growth Considering what you have learned about genetic changes underlying the formation and progression of tumors propose an explanation for the decline in efficacy of Gleevec over time Limit your answer to 1 2 sentences